{
    "nctId": "NCT00324363",
    "title": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Treated with a stable dose of one of the following for at least 3 months prior to screening: >=1000 mg/day immediate-release metformin"
                    },
                    {
                        "type": "variable",
                        "value": "Treated with a stable dose of one of the following for at least 3 months prior to screening: metformin >=1000 mg/day and sulfonylurea"
                    },
                    {
                        "type": "variable",
                        "value": "Treated with a stable dose of one of the following for at least 3 months prior to screening: sulfonylurea/metformin combination therapy"
                    },
                    {
                        "type": "variable",
                        "value": "HbA1c between 7.1% and 11.0%, inclusive."
                    },
                    {
                        "type": "variable",
                        "value": "Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 21 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 75 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Have participated in this study previously, or any other study using exenatide or GLP-1 analogs."
                            },
                            {
                                "type": "variable",
                                "value": "Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening."
                            },
                            {
                                "type": "variable",
                                "value": "Have characteristics contraindicating metformin or sulfonylurea use."
                            },
                            {
                                "type": "variable",
                                "value": "Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening."
                            },
                            {
                                "type": "variable",
                                "value": "Have used drugs for weight loss within 1 month of screening."
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2'), Symbol('HbA1c between 7.1% and 11.0%, inclusive.'), Symbol('Must have maximum age of 75 Years'), Symbol('Must have minimum age of 21 Years'), Symbol('Treated with a stable dose of one of the following for at least 3 months prior to screening: >=1000 mg/day immediate-release metformin'), Symbol('Treated with a stable dose of one of the following for at least 3 months prior to screening: metformin >=1000 mg/day and sulfonylurea'), Symbol('Treated with a stable dose of one of the following for at least 3 months prior to screening: sulfonylurea/metformin combination therapy'), Not(Or(Symbol('Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.'), Symbol('Have characteristics contraindicating metformin or sulfonylurea use.'), Symbol('Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.'), Symbol('Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.'), Symbol('Have used drugs for weight loss within 1 month of screening.'))))"
}